Skip to content
  • Saturday, 12 September 2026
  • 6:32 pm
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Eli Lilly’s triple agonist achieves 16.8% weight loss in phase 3 trial
Laboratory Automation & Robotics

Eli Lilly’s triple agonist achieves 16.8% weight loss in phase 3 trial

Lana Keisha Apr 3, 2026 0

Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial, revealing that its investigational triple agonist,…

Read More
Laboratory Automation & Robotics

Eli Lilly’s Triple Agonist Retatrutide Achieves Remarkable 16.8% Weight Loss in Phase 3 Trial for Type 2 Diabetes

Lana Keisha Mar 27, 2026 0

Eli Lilly and Company has announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…

Read More
Laboratory Automation & Robotics

Eli Lilly’s Triple Agonist Achieves 16.8% Weight Loss in Phase 3 Trial for Type 2 Diabetes, Signaling Major Therapeutic Advance

Lana Keisha Mar 19, 2026 0

Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…

Read More

Posts pagination

1 2
FDA Commissioner Marty Makary Resigns Amid Pressure and Widespread CriticismJohns Hopkins Researchers Identify Ancient Brainstem Neurons Crucial for Selective Attention and Distraction FilteringJ&J Poster Puts Spravato Remission Data at Center of Treatment-Resistant Depression Growth PushScience News: A Centennial of Illuminating the World of Science
Japan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactMEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals PlummetLLMOps in 2026: The 10 Tools Every Team Must Have
Attention Unleashed: Rethinking ADHD as a Conduit for Creative Innovation in the Modern Neurological LandscapeHarmonic Shielding: Harvard Researchers Use Microscopic Sound Waves to Protect Fragile Quantum InformationSolstice Oncology Secures $225m in Series A Financing to Advance Neoadjuvant Immuno-Oncology Therapy PorustobartScience News: A Century of Independent Scientific Journalism and the Evolution of Public Literacy
YOU MAY HAVE MISSED
Neuroscience & Brain Research
Attention Unleashed: Rethinking ADHD as a Conduit for Creative Innovation in the Modern Neurological Landscape
Rifan Muazin Sep 12, 2026
Advanced Materials Science
Harmonic Shielding: Harvard Researchers Use Microscopic Sound Waves to Protect Fragile Quantum Information
Nila Kartika Wati Sep 12, 2026
Pharmaceutical R&D
Solstice Oncology Secures $225m in Series A Financing to Advance Neoadjuvant Immuno-Oncology Therapy Porustobart
Teuku Ryan Sep 12, 2026
Environmental & Analytical Chemistry
Science News: A Century of Independent Scientific Journalism and the Evolution of Public Literacy
Abdurrohim Arsyad Sep 12, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ